The recently published JETSTREAM Calcium Study was a prospective, single-arm, multicenter study to evaluate the effect of the JETSTREAM™ Atherectomy System (Boston Scientific Corporation) when treating severely calcified peripheral arterial lesions in the common femoral, superficial femoral, or popliteal arteries causing claudication. The main question was whether the JETSTREAM Atherectomy System was effective in removing calcification. This was evaluated using both quantitative and qualitative intravascular ultrasound (IVUS), by comparing preintervention and postatherectomy IVUS images. The two major findings were as follows: The JETSTREAM Atherectomy System removed and modified moderate to severe superficial calcium to achieve significant lumen gain as standalone therapy; and adjunctive balloon angioplasty after calcium modification with the JETSTREAM Atherectomy System showed further lumen increase without major complications. In this study, the JETSTREAM 2.1/3.0 mm device was used for all procedures without distal protection. There were no major adverse events up to 30 days postprocedure.

WHY AN IVUS STUDY IS UNIQUE
Calcium was screened by angiography to identify moderate to severe obstructive intraluminal calcification in the common femoral, superficial femoral, or popliteal arteries. Lesions were evaluated by IVUS. Patients identified by angiography as possible candidates were included in the final analysis only if there was superficial calcium that had an arc > 90° and a length > 5 mm. Overall, 55 patients were screened; however, only 26 patients met the inclusion criteria. Half of the lesions identified angiographically as having moderate to severe calcification did not have severe superfi-

CASE STUDY 1:
COMMON FEMORAL*

Figure 1. Before (A) and after (B) successful revascularization of a highly stenotic left common femoral artery.

Figure 2. Pre-atherectomy IVUS image of the common femoral artery (lumen area = 2.4 mm²) (A) compared to post-JETSTREAM image (B) illustrates impressive luminal gain and a circumferential lumen created with standalone JETSTREAM Atherectomy (lumen area = 8.6 mm²), Boston Scientific images on file from the JETSTREAM Calcium Study.

*Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.
cial calcium (calcium within the lumen) at the lesion site as determined by IVUS. In these lesions, superficial calcification existed only in nonstenotic segments, or only deep calcification (calcium within the vessel wall) was present at the stenosis site. Therefore, the first finding of this study was the limitation of peripheral angiography to detect and localize calcification in peripheral arterial lesions. Deep calcification may not affect luminal gain (ie, create a stenosis). Therefore, the differentiation between superficial and deep calcification and their respective roles in severe stenosis is important when evaluating the true efficacy of any atherectomy procedure and device. These findings are similar to the data reported by Mintz et al in coronary artery lesions. In that study, IVUS detected calcium in 841 of 1,155 coronary artery lesions (73%), while angiography detected calcium in only 440 (38%). Therefore, the overall sensitivity of angiography relative to IVUS was 48%, with a specificity of 89%.

**SIGNIFICANT LUMINAL GAIN ACHIEVED WITH JETSTREAM ATERECTOMY**

For the patients who were ultimately included in the study, first the preintervention and postatherectomy IVUS lumens were outlined. Second, the postatherectomy IVUS images were overlaid onto their respective preintervention images. Assuming there was no change in total arterial area, the change in lumen area was attributed to either calcified plaque or noncalcified plaque removal (Figure 3). At the slice with the maximum calcium reduction, the lumen area increased from 6.6 ± 3.7 mm² preintervention to 10 ± 3.6 mm² ($P = .001$) after atherectomy. The decrease in calcium area, measured as 2.8 ± 1.6 mm², was responsible for 86% ± 23% of the lumen area increase. Additionally, the arc of reverberations increased from 25° (range, 15°–35°) to 70° (range, 46°–95°), $P = .001$, indicating device-related modification of calcium. Therefore, the second lesson was that the JETSTREAM Atherectomy System increased lumen dimensions by calcium removal as well as by calcium modification (increase in reverberations).

At the slice with the maximum calcium reduction, the lumen area increased from 6.6 ± 3.7 mm² preintervention to 10 ± 3.6 mm² ($P = .001$) after atherectomy.
VESSEL EXPANSION WITHOUT VESSEL DAMAGE

In the 11 lesions that had postadjunctive balloon IVUS images, the minimum lumen area increased further from 7 mm² (range, 6.4–7.8 mm²) after atherectomy to 11.9 mm² (range, 10.3–13.5 mm²) after adjunct balloon inflation (P < .01). However, the prevalence of dissections also increased from 3/11 after atherectomy to 8/11 after adjunct balloon inflations (P = .03). However, the maximum angle of the dissection flap was minor (42° [range, 17°–66°]) with a preserved lumen area (15.6 mm² [range, 13.4–17.7 mm²]) within the dissection. The dissections were non-flow limiting. Also, the higher resolution of IVUS imaging versus angiography most likely led to a higher detection rate. Thus, the third and final lesson was that the JETSTREAM Atherectomy System allowed additional lumen increase by facilitating vessel expansion without significant vessel damage (ie, dissection), presumably because of calcium modification. A representative case is shown in Figure 4.

CONCLUSION

Severely calcified lesions may cause damage to the polymer/drug coating of a drug-eluting stent, resulting in inadequate drug delivery.3,4 Although there is accumulating evidence in coronary artery intervention showing that calcified lesions have worse outcomes compared to noncalcified lesions,5,6 the clinical impact of superficial calcium removal in peripheral artery disease in respect to effectiveness of drug-coated balloons or drug-eluting stents needs further investigation.7

Akiko Maehara, MD, is with Columbia University Medical Center and the Cardiovascular Research Foundation in New York, New York. Dr. Maehara has disclosed that she receives a grant from and is a consultant to, Boston Scientific Corporation.

Gary S. Mintz, MD, is with the Cardiovascular Research Foundation in New York, New York. Dr. Mintz has disclosed that he receives grant support and is a consultant for Boston Scientific Corporation and Volcano Corporation.

William A. Gray, MD, is with Columbia University Medical Center in New York, New York. He has disclosed that he is a consultant to Boston Scientific Corporation. Dr. Gray may be reached at (212) 304-5697; wg2131@columbia.edu.

Acknowledgement: The authors thank investigators Thomas M. Shimshak, MD; Joseph J. Ricotta II, MD, MS; Venkatesh Ramaiah, MD; Malcolm T. Foster III, MD; and Thomas P. Davis, MD, for their work on the JETSTREAM Calcium Study.


---

CASE STUDY 2: DISTAL SFA/PROXIMAL POPLITEAL*

Figure 5. Successful debulking with the JETSTREAM Atherectomy System in a distal right SFA/proximal popliteal artery lesion (A). The pre-atherectomy IVUS image (B) reveals a lumen area of 2.5 mm². The post-atherectomy images (C and D) reveal a lumen area of 7.6 mm² and impressive debulking with JETSTREAM Atherectomy even before adjunctive therapy. Boston Scientific images on file from the JETSTREAM Calcium Study.

*Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.
ABBREVIATED STATEMENTS

JETSTREAM CATHETERS COMBINED WITH CONSOLE

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete “Instructions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions.

Catheter INDICATIONS

The Jetstream System is intended for use in atherectomy of the peripheral vasculature and to break apart and remove thrombus from upper and lower extremity peripheral arteries. It is not intended for use in coronary, carotid, iliac or renal vasculature.

Console INDICATIONS

The PV Console is designed for use only with the Jetstream Catheter and Control Pod. See the current revision of the applicable Catheter and Control Pod Instructions for Use for further information.

CONTRAINDICATIONS

No known contraindications.

Catheter WARNINGS/ PRECAUTIONS

• The Jetstream Catheter and Control Pod may only be used with the PV Console.
• Take care to avoid being pinched when closing the aspiration and infusion pump doors. Use room temperature infusate only. Use of heated infusate may lead to wrinkling, ballooning and/or bursting of the outer catheter sheath.
• Do not bend or kink the Catheter during setup or during the procedure. This may damage the device and lead to device failure.
• Operating the Catheter over a kinked guidewire may cause vessel damage or guidewire fracture.
• During treatment, do not allow the Catheter tip within 10.0 cm of spring tip portion of the guidewire. Interaction between the Catheter Tip and this portion of the guidewire may cause damage to or detachment of the guidewire tip or complicate guidewire management.
• The guidewire must be in place prior to operating the Catheter in the patient. Absence of the guidewire may lead to instability of the Catheter and cause potential vessel damage.
• Do not inject contrast while the device is activated.
• If the guidewire is accidentally retracted into the device during placement or treatment, stop use, and remove the Catheter and the guidewire from the patient. Verify that the guidewire is not damaged before reinserting the guidewire. If damage is noticed, replace the guidewire.
• Check the infusate bag frequently and replace when needed. Do not run the JETSTREAM System without infusate as this may cause device failure.
• Hold the guidewire firmly during catheter retraction process. Failure to do so may result in guidewire rotation within the vessel.
• Do not manipulate the Catheter against resistance unless the cause for that resistance has been determined.

• Use only listed compatible guidewires and introducers with the Jetstream System. The use of any supplies not listed as compatible may damage or compromise the performance of the Jetstream System.
• Prior to use of the Jetstream System, confirm the minimum vessel diameter proximal to the lesion per the following:
  Jetstream SC Atherectomy Catheter 1.6 Minimum Vessel Diameter Proximal to Lesion 2.5 mm
  Jetstream SC Atherectomy Catheter 1.8 Minimum Vessel Diameter Proximal to Lesion 2.75 mm
  Jetstream XC Atherectomy Catheter 1.8 Minimum Vessel Diameter, Blades Down 3.0 mm; Minimum Vessel Diameter, Blades Up 4.0 mm
  Jetstream XC Atherectomy Catheter 2.4-3.4 Minimum Vessel Diameter, Blades Down 3.5 mm; Minimum Vessel Diameter, Blades Up 4.5 mm

Console WARNINGS/ PRECAUTIONS

• WARNING: To avoid the risk of electric shock, this equipment must only be connected to a supply mains with protective earth.
• Do not open either pump door during operation of the System. Doing so could result in loss of aspiration and/or infusion and will halt device activation.
• Ensure the PV Console display is visible during the entire procedure.
• Observe normal safety practices associated with electrical/electronic medical equipment.
• Avoid excessive coiling or bending of the power cables during storage.
• Store the PV Console using appropriate care to prevent accidental damage.
• Do not place objects on the PV Console.
• Do not immerse the PV Console in liquids.

ADVERSE EVENTS

Potential adverse events associated with use of this device and other interventional catheters include, but are not limited to the following (alphabetical order):
• Abrupt or sub-acute closure • Amputation • Bleeding complications, access site • Bleeding complications, non-access site • Death • Dissection • Distal emboli • Hypotension • Infection or fever • Perforation • Restenosis of the treated segment • Vascular complications which may require surgical repair • Thrombus • Vasospasm

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. This material is not for use or distribution in France.

All Trademarks are the property of their respective owners. © 2015 Boston Scientific Corporation or its affiliates. All rights reserved. PI-306610-AA DEC 2015